Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP Immune Modulation-2: eritoran vs placebo in hospitalized adults with moderate COVID-19
jRCT2031200443Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing E5564 group with Placebo group (2 arms). Started Mar 2021; status: completed.
02
Drugs
eritoran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200443.